Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Challenges Remain in Prostate Cancer Paradigm

Caroline Seymour
Published: Tuesday, Sep 25, 2018

Walter M. Stadler, MD

Walter M. Stadler, MD

Following the wave of FDA approvals in prostate cancer, Walter M. Stadler, MD, explained that the field has undergone a dramatic transformation, but research should be focused on immunotherapy, sequencing strategies, and biomarkers.

It has been theorized that PARP inhibitors provide synergistic effects in combination with immunotherapy, and a cohort of the ongoing phase I KEYNOTE-365 trial is examining the combination of pembrolizumab (Keytruda) and olaparib (Lynparza; NCT02861573) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Moreover, a randomized phase II trial is investigating the combination of abiraterone acetate (Zytiga) and prednisone with or without olaparib versus single-agent olaparib in the same population (NCT03012321).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication